NanoBio Corporation (NanoBio) has received an award from the National Institute of Allergy and Infectious Diseases, a Division of The National Institute of Health, to fund vaccine research associated with “Innate Immune Receptors and Adjuvant Discovery.”
Reportedly, NanoBio is the principal subcontractor for the $9.3m contract awarded to the University of Michigan. NanoBio will receive a subcontract of approximately $4.1m over the research period to support efforts aimed at developing nanoemulsion-based mucosal vaccine adjuvants for a wide variety of antigens.
As announced earlier, the FDA has approved NanoBio’s Investigational New Drug (IND) application for the phase 1 clinical study of NB-1008, a seasonal influenza vaccine administered via a nasal dropper. The phase 1 study is currently ongoing.
David Peralta, CFO and COO at NanoBio, said: “NanoBio’s nanoemulsion-based vaccine adjuvant platform has consistently demonstrated the ability to elicit robust systemic, cellular and mucosal immunity, based on studies we’ve conducted in numerous diseases using various antigen types. This award will fund extensive additional research that will allow NanoBio and the University of Michigan to further advance our adjuvant platform for vaccines. This funding will enable NanoBio to make tremendous advances in terms of mucosal vaccination, which could provide significant advantages with respect to disease protection worldwide.”